Novo Nordisk: guidance raised for 2023
(CercleFinance.com) - Novo Nordisk has raised its sales and operating profit growth forecasts at constant exchange rates (CER) for 9m 2023 and FY 2023.
In the first nine months of 2023, the Danish pharmaceutical company estimates a 33% increase in sales and a 37% rise in operating profit, excluding currency effects.
Therefore, the group specialising in diabetes treatment is now anticipating FY growth (CER) of 32%-38% for sales, with EBIT up 40%-46%, compared with previous target ranges of 27%-33% and 31%-37% respectively.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
In the first nine months of 2023, the Danish pharmaceutical company estimates a 33% increase in sales and a 37% rise in operating profit, excluding currency effects.
Therefore, the group specialising in diabetes treatment is now anticipating FY growth (CER) of 32%-38% for sales, with EBIT up 40%-46%, compared with previous target ranges of 27%-33% and 31%-37% respectively.
Copyright (c) 2023 CercleFinance.com. All rights reserved.